Despazol - means for treatment of a peptic ulcer and a gastroesophageal reflux disease. Inhibitors of the proton pump. Esomeprazole.

Structure

Active ingredient: esomeprazole.

1 bottle contains sodium esomeprazole that is equivalent esomeprazole of 40 mg.

Excipients: anhydrous attracts (E 421), sodium a carbonate.

Contraindication

• Hypersensitivity to active ingredient of esomeprazole, another substituted benzimidazole or to any of excipients of this medicine.
• Esomeprazole should not be applied along with atazanaviry, nelfinaviry.

Route of administration

to Patients who cannot take the medicament orally can administer the medicament parenterally in a dose of 20-40 mg of 1 times a day. The dose for patients with reflux an esophagitis makes 40 mg of 1 times a day. The dose for patients who receive symptomatic treatment of a reflux disease makes 20 mg of 1 times a day.

Pregnant women

Data on use of esomeprazole during pregnancy are limited to

Feature

to Apply

to children aged from 1 year as means to anti-secretory therapy in case oral administration of medicament is impossible.

Drivers

It is improbable

that Esomeprazole affected ability to drive the car and to work with mechanisms. During treatment, side reactions from nervous system or organs of sight can be observed.

Overdose

Experience deliberate overdoses is very limited to

now. Manifestations from digestive tract and weakness were symptoms which resulted oral administration of a dose of 280 mg. Single oral administration of 80 mg of esomeprazole and introduction of 308 mg of esomeprazole within 24 hours of consequences did not cause. Specific antidote is unknown. Esomeprazole considerably contacts proteins of blood plasma and therefore it is badly removed by means of dialysis. As well as in case of any overdose, it is necessary to provide symptomatic treatment and to accept the general supporting measures.

Side effects

from blood and lymphatic system

it is rare: leukopenia, thrombocytopenia.

It is very rare: agranulocytosis, pancytopenia.

from the immune system

it is rare: reactions of hypersensitivity, for example, fever, Quincke's disease and anaphylactic reactions / shock.

from metabolism and food

Infrequently: peripheral hypostasis.

it is rare: hyponatremia.

Unknown frequency: a hypomagnesiemia (see the Section "Features of Use"); the heavy hypomagnesiemia can correlate with a hypocalcemia.

Mental disorders

Infrequently: insomnia.

it is rare: agitation, confusion of consciousness, depression.

It is very rare: aggression, hallucinations.

from nervous system

it is frequent: headache.

Infrequently: dizziness, paresthesias, drowsiness.

it is rare: disturbance of flavoring feelings.

from organs of sight

Infrequently: indistinct sight.

from organs of hearing and balance

Infrequently: vertigo.

from respiratory organs, a thorax and mediastinum

it is rare: bronchospasm.

from digestive system

it is frequent: abdominal pain, constipation, diarrhea, meteorism, nausea / vomiting.

Infrequently: dryness in a mouth.

it is rare: stomatitis, gastrointestinal candidiasis.

Unknown frequency: microscopic colitis.

Interaction

It is noted interaction of omeprazolum with some inhibitors of protease. The clinical importance and mechanisms of these interactions are not always known. Increase in level rn gastric juice during therapy by omeprazolum can change absorption of inhibitors of protease. Other mechanisms of interaction are possible because of suppression of CYP2C19. Decrease in serumal levels of an atazanavir and nelfinavir was noted at simultaneous use of omeprazolum therefore in passing it is not recommended to use these drugs. Simultaneous use of omeprazolum (40 mg of 1 times a day) from atazanaviry 300 mg / ritonaviry 100 mg at healthy volunteers gave considerable decrease in exposure of an atazanavir (decrease in AUC, Cmax and Cmin approximately for 75%). Increase in a dose of an atazanavir to 400 mg did not compensate influence of omeprazolum on exposure of an atazanavir. Simultaneous use of omeprazolum (20 mg a day) from atazanoviry 400 mg / ritonaviry 100 mg at healthy volunteers reduced exposure of an atazanavir approximately by 30% in comparison with the exposure noted at use of an atazanavir of 300 mg / a ritonavira of 100 mg of 1 times in day without use of omeprazolum in a dose of 20 mg in day. Simultaneous use of omeprazolum (40 mg a day) reduced average AUC, Cmax and Cmin values of a nelfinavir by 36-39%, and average AUC, Cmax and Cmin values pharmacological of an active metabolite of M8 for 75-92%.

to Store

in original packing at a temperature not above 25 °C. To store out of children's reach.

Expiration date: 2 years.